Date published: 2025-9-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

GPR89C Inhibitors

The chemical class of GPR89C Inhibitors includes compounds that modulate the activity of the GPR89C protein through various indirect mechanisms. These compounds operate through diverse pathways, influencing different cellular processes and signaling pathways related to GPR89C's function.

Compounds like Sodium butyrate and Forskolin, known for their roles in histone deacetylation and adenylyl cyclase activation respectively, might influence the transcriptional regulation and cAMP-mediated signaling of GPR89C. Similarly, PD98059 and LY294002, which target MEK and PI3K pathways, respectively, could affect GPR89C's function in cell signaling and survival.

Furthermore, Rapamycin's role in mTOR inhibition and SB203580's influence on p38 MAP kinase pathways highlight the complex interactions in cellular growth and stress response mechanisms that can affect GPR89C. U0126 and Wnt Inhibitor I further illustrate the modulation of ERK and Wnt/β-catenin signaling pathways, respectively, in relation to GPR89C.

Additionally, Sunitinib and Bafilomycin A1, through their roles in angiogenesis and vesicular transport, demonstrate the breadth of cellular processes that can intersect with GPR89C's activity. JNK Inhibitor II and DAPT, targeting c-Jun N-terminal kinase and γ-secretase respectively, underscore the diverse regulatory pathways that can be leveraged to modulate GPR89C.

In summary, the chemical class of GPR89C Inhibitors represents a diverse array of compounds with varied molecular actions. These inhibitors, through their interactions with different cellular pathways, offer multiple strategies for modulating the activity of GPR89C. Understanding these diverse mechanisms is crucial for comprehending the multifaceted nature of protein regulation and opens up avenues for research into the modulation of specific proteins like GPR89C.

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Sodium Butyrate

156-54-7sc-202341
sc-202341B
sc-202341A
sc-202341C
250 mg
5 g
25 g
500 g
$30.00
$46.00
$82.00
$218.00
18
(3)

Histone deacetylase inhibitor, may affect gene expression including genes related to GPR89C function.

Forskolin

66575-29-9sc-3562
sc-3562A
sc-3562B
sc-3562C
sc-3562D
5 mg
50 mg
1 g
2 g
5 g
$76.00
$150.00
$725.00
$1385.00
$2050.00
73
(3)

Adenylyl cyclase activator, potentially altering cAMP levels and influencing GPR89C-related signaling pathways.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

MEK inhibitor, could modulate MAPK/ERK pathway potentially intersecting with GPR89C function.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

PI3K inhibitor, possibly affecting GPR89C through the PI3K/Akt pathway.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

mTOR inhibitor, could impact cellular processes related to GPR89C through mTOR pathways.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

p38 MAP kinase inhibitor, may modulate stress-activated protein kinase pathways affecting GPR89C.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

MEK inhibitor, could impact ERK signaling pathways related to GPR89C activity.

Wnt Agonist

853220-52-7sc-222416
sc-222416A
5 mg
25 mg
$154.00
$597.00
23
(2)

Inhibits Wnt/β-catenin pathway, could influence GPR89C related to cell signaling and development.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$150.00
$920.00
5
(0)

Tyrosine kinase inhibitor, potentially affecting angiogenesis pathways related to GPR89C.

Bafilomycin A1

88899-55-2sc-201550
sc-201550A
sc-201550B
sc-201550C
100 µg
1 mg
5 mg
10 mg
$96.00
$250.00
$750.00
$1428.00
280
(6)

V-ATPase inhibitor, could influence vesicular transport pathways intersecting with GPR89C function.